Department of Urology Surgery, Chengdu Second People's Hospital, Chengdu, Sichuan, China.
Department of Pathology, Chengdu Second People's Hospital, Chengdu, Sichuan, China.
Medicine (Baltimore). 2024 Jul 19;103(29):e38858. doi: 10.1097/MD.0000000000038858.
Bladder cancer (BC) is fatal during muscle invasion and treatment progress is limited. In this study, we aimed to construct and validate basement membrane (BM)-associated gene prognosis to predict BC progression and tumor immune infiltration correlation. We choreographed BM-related genes in the Cancer Genome Atlas (TCGA) database using COX regression and least absolute shrinkage and selection operator (LASSO) analysis, and the predictive value of BM-related genes was further validated by the GSE32548, GSE129845, and immunohistochemistry staining. All analyses were performed with R-version 4.2.2, and its appropriate packages. Three genes were identified to construct a gene signature to predictive of BC prognosis. We divided the TCGA database into 2 groups, and patients in the high-risk group had worse overall survival (OS) than those in the low-risk group. In GSE32548, we confirmed that patients in the high-risk group had a poorer prognosis compared to those in the low-risk group in terms of OS. Immunohistochemical staining of EPEMP1, GPC2, and ITGA3 showed significantly higher expression at the protein level in BC tissues than in normal tissues. The Spearman analysis showed risk score was positively correlated with B cell naïve, Macrophages M2, and Mast cells resting. stromal score, immune score, and ESTIMATE scores were significantly higher in the high-risk group. drugs sensitivity analysis showed IC50 of Cisplatin, Gemcitabine, and Methotrexate in the high-risk group was significantly higher than that in the low-risk group. We identified 3 prognostic genes from a novel perspective of BM genes as effective risk stratification tools for BC patients.
膀胱癌(BC)在肌肉侵犯时是致命的,治疗进展有限。在这项研究中,我们旨在构建和验证基底膜(BM)相关基因预后,以预测 BC 进展和肿瘤免疫浸润相关性。我们使用 COX 回归和最小绝对值收缩和选择算子(LASSO)分析在癌症基因组图谱(TCGA)数据库中编排 BM 相关基因,并且通过 GSE32548、GSE129845 和免疫组织化学染色进一步验证 BM 相关基因的预测价值。所有分析均使用 R 版本 4.2.2 和其适当的软件包进行。确定 3 个基因构建基因特征来预测 BC 预后。我们将 TCGA 数据库分为 2 组,高风险组患者的总生存期(OS)比低风险组患者更差。在 GSE32548 中,我们证实高风险组患者的 OS 预后比低风险组患者更差。EPEMP1、GPC2 和 ITGA3 的免疫组织化学染色显示 BC 组织中蛋白水平的表达明显高于正常组织。Spearman 分析显示风险评分与 B 细胞幼稚、巨噬细胞 M2 和静止肥大细胞呈正相关。高风险组的基质评分、免疫评分和 ESTIMATE 评分明显更高。药物敏感性分析显示高风险组的 Cisplatin、Gemcitabine 和 Methotrexate 的 IC50 明显高于低风险组。我们从 BM 基因的新视角确定了 3 个预后基因,作为 BC 患者有效的风险分层工具。